Clinical TrialJun 4, 2026, 08:41 AM
GH Research's GH001 PPD trial shows 100% remission; CINP presentations
AI Summary
GH Research PLC announced the publication of full Phase 2a trial results for inhaled mebufotenin (GH001) in postpartum depression (PPD), showing rapid and sustained remission in all patients. The trial met its primary endpoint with a significant reduction in MADRS scores and demonstrated improved maternal functioning. Additionally, the company announced the acceptance of two oral presentations at CINP 2026, which will present data from its Phase 2b trial of GH001 in treatment-resistant depression (TRD).
Key Highlights
- GH Research published full Phase 2a trial results for inhaled mebufotenin (GH001) in postpartum depression (PPD).
- Primary endpoint met: Mean MADRS reduction of -35.4 points from baseline to Day 8 (P<0.0001).
- 100% of patients (10/10) achieved remission within two hours of dosing, sustained through Day 8.
- Patients showed improved maternal functioning with a mean 34.1-point (56%) increase on the Barkin Index.
- GH001 was well-tolerated with no serious adverse events reported.
- Two oral presentations on Phase 2b GH001 data for treatment-resistant depression (TRD) accepted at CINP 2026.
Price Impact
More from GHRS